The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: A sub‐analysis of the BRAVO study
Brian O’Neill(Henry Ford Health System), Mauricio G. Cohen(Santa Ana College), Samantha Sartori(Icahn School of Medicine at Mount Sinai), Annapoorna Kini(Mount Sinai Medical Center), Roxana Mehran(Mount Sinai Hospital), Samin K. Sharma(Mount Sinai Health System), Claudia Martinez, Pedro Martinez‐Clark(University of Miami), George Dangas(Mount Sinai Hospital), Alan W. Heldman(University of Miami), David Knopf(University of Miami), Usman Baber(Icahn School of Medicine at Mount Sinai), Evan Jacobs(University of Miami), Jason C. Kovacic(Victor Chang Cardiac Research Institute), Vikas Singh(University of Miami), William W. O’Neill(Henry Ford Health System), Carlos E. Alfonso(University of Miami), Jennifer Yu(UNSW Sydney)
Cited by 17
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
|Circulation|2011|3.3k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2011|2.2k